Uncategorized

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

Published

2 weeks ago

on

Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson & Johnson.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version